公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors | Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. | Journal for ImmunoTherapy of Cancer | 56 | 46 | |
2020 | PD-1 blockade in anaplastic thyroid carcinoma | Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; CHIA-CHI LIN ; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M. | Journal of Clinical Oncology | 165 | 126 | |
2018 | Pembrolizumab for the treatment of advanced salivary gland carcinoma | Cohen R.B.; Delord J.-P.; Doi T.; Piha-Paul S.A.; Liu S.V.; Gilbert J.; Algazi A.P.; Damian S.; RUEY-LONG HONG ; Le Tourneau C.; Day D.; Varga A.; Elez E.; Wallmark J.; Saraf S.; Thanigaimani P.; Cheng J.; Keam B. | American Journal of Clinical Oncology: Cancer Clinical Trials | 151 | 119 | |
2019 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | Mehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B. | BMC Cancer | 135 | 108 |